34 stories mentioning SHA:600196Updated just now
Every FINWIRES story that references SHA:600196, newest first.
Shanghai Fosun Pharmaceutical (SHA:600196) provided a joint liability guarantee of 248.6 million yuan for wholly-owned subsidiary Fosun Pharma Industry's 84-month loan from China Everbright Bank.The guarantee, effective June 22, falls within the company's 35 billion yuan guarantee limit, according to a Monday filing with the Shenzhen bourse.Shares of the pharmaceutical company rose 1% in recent trade.
Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) subsidiary, Shanghai Henlius Biotech (HKG:2696), passed a drug GMP or good manufacturing practice inspection, according to a Shanghai bourse filing on Thursday.The Shanghai Municipal Medical Products Administration made the inspection at Henlius' manufacturing facility in Songjiang District, which produces the breast cancer drug Hanbeiyou or pertuzumab injection.The company was found to be compliant with GMP requirements.The pharmaceutical company's Shanghai shares rose 2% during the morning trade.
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196), through its subsidiary Shanghai Henlius Biotech (HKG:2696), received approval from China's National Medical Products Administration for the clinical trials of HLX3902 injection, according to a Shanghai bourse filing on Thursday.The drug will be tested as a treatment for metastatic castration-resistant prostate cancer and other advanced solid tumors.The pharmaceutical company's Shanghai shares rose 2% during the morning trade.
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) said the drug registration application for an additional indication of Luvometinib Tablets was approved by China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.Shares of the pharmaceutical company were down nearly 2% in Tuesday afternoon trading.The approved indication is for the treatment of pediatric patients aged two years and older with relapsed or refractory Langerhans cell histiocytosis.The drug was developed by Shanghai Fosun Pharmaceutical Industrial Development, a unit of Fosun Pharmaceutical.
Shanghai Fosun Pharmaceutical (SHA:600196) subsidiary Yaoyou Pharmaceutical signed an exclusive license agreement with Chongqing Genrix Biopharmaceutical (SHA:688443) for bispecific antibody GR1803.The deal includes up to 600 million yuan in upfront, milestone and technology transfer payments, plus tiered royalties, according to a Friday filing with the Shanghai bourse.Yaoyou Pharmaceutical will act as marketing authorization holder for mainland China, Hong Kong, Macau and Taiwan.GR1803 targets multiple myeloma and lupus.Shares of the pharmaceutical company were up 2% in recent trade.
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196), through subsidiary Fosun Pharma Industry, plans to invest 414.4 million yuan to participate in the Series B financing of Xingyao Kunze, according to a Wednesday filing on the Shanghai bourse.Xingyao Kunze develops drugs for liver diseases. Its pipeline products are HT-101 and HT-102, and the combination of these drugs.After the completion of the funding round, Fosun Pharma Industry is expected to own 20.9% of Xingyao Kunze.The pharmaceutical company's Hong Kong shares fell by less than 2% during the afternoon trade.
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma obtained drug registration approval for the Levofloxacin Injection from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.The approved indication is for various mild, moderate, and severe infections caused by susceptible bacteria, including pneumonia, acute bacterial sinusitis, skin infections urinary tract infections, and more.
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) subsidiary Fosun Pharma Industrial signed an exclusive option agreement with South Korea's AriBio for AR1001, an oral drug candidate for early Alzheimer's disease.The unit will pay a $60 million option fee and can exercise the license within 90 days after receiving topline data from an ongoing global Phase III trial.If exercised, Fosun Pharma Industrial will pay up to $180 million in upfront and regulatory milestones, plus tiered royalties.Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade on the Shanghai and Hong Kong bourses.
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Hebei Wanbang Folon Pharmaceutical's drug registration application for Tao Hong Si Wu Tang Granules was accepted by China's National Medical Products Administration.The drug is intended to be used for blood deficiency and blood stasis syndrome, according to a Wednesday Hong Kong bourse filing.
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit's drug registration application for Venlafaxine Hydrochloride Sustained-release Tablets obtained approval from China's National Medical Products Administration.The approved indication for the drug, developed by Fosun Pharma (Xuzhou), is to treat depression and generalized anxiety disorder, according to a Friday Hong Kong bourse filing.
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma's drug registration application for the Sodium Nitroprusside Injection was approved by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The approved indication is for hypertensive emergencies and acute heart failure.
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) logged a 14% rise in its attributable profit for the first quarter of 2026 to 870.8 million yuan from 764.8 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.The pharmaceutical company's Hong Kong shares fell nearly 2% in late morning trade Wednesday.Earnings per share were 0.33 yuan, compared with 0.29 yuan in the prior year.Operating revenue gained nearly 7% to 10.1 billion yuan, figures showed.
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Fosun Kairos (Shanghai) Biological Technology obtained approval for a phase I/II clinical trial of FKC289 injection from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The drug will be tested for the treatment of primary light chain amyloidosis and membranous nephropathy.The subsidiary will begin the trial once conditions are met.
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma's drug registration application of Flurbiprofen Axetil Injection was approved by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approved indication is for post-surgical and cancer-related analgesia.
Showing 21-34 of 34
